A randomized, double-blind, placebo-controlled trial with mannan-conjugated birch pollen allergoids.
allergic rhinoconjunctivitis
allergoid
birch pollen
combined symptom and medication score
mannan conjugate
Journal
Allergy
ISSN: 1398-9995
Titre abrégé: Allergy
Pays: Denmark
ID NLM: 7804028
Informations de publication
Date de publication:
12 Oct 2023
12 Oct 2023
Historique:
revised:
12
09
2023
received:
24
05
2023
accepted:
21
09
2023
medline:
12
10
2023
pubmed:
12
10
2023
entrez:
12
10
2023
Statut:
aheadofprint
Résumé
There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis. For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan-conjugated birch pollen allergoids at five pre-seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti-allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed. The highest dose of mannan-conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose-dependent manner (3.6- and 4.5-fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to -70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II). All doses of mannan-conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.
Sections du résumé
BACKGROUND
BACKGROUND
There is still great need to develop new strategies to improve the efficacy of allergen immunotherapies with optimal safety standards for patients. A new promising approach is to couple allergoids to mannan. The objective of this phase IIa/IIb study was to identify the optimal dose of mannan-conjugated birch pollen allergoids for the short-course treatment of birch pollen-induced allergic rhinoconjunctivitis.
METHODS
METHODS
For this prospective, randomized, double-blind, placebo-controlled, dose-finding study, 246 birch pollen-allergic adults received 0.5 mL placebo or 1000, 3000 or 10,000 mTU/mL of mannan-conjugated birch pollen allergoids at five pre-seasonal visits. Efficacy was assessed by comparing allergic rhinoconjunctivitis symptoms and use of anti-allergic medication during the peak of the birch pollen season 2020. Immunologic, tolerability and safety effects were also analysed.
RESULTS
RESULTS
The highest dose of mannan-conjugated birch pollen allergoids reduced the combined symptom and medication score during the peak birch pollen season by a median of 24.7% compared to placebo. The production of Bet v 1 specific IgG4 significantly increased in a dose-dependent manner (3.6- and 4.5-fold) in the 3000 and 10,000 mTU/mL groups. The Bet v 1 specific IgE/IgG4 ratio was also strongly reduced (up to -70%). No fatalities nor serious adverse events were reported, and no adrenaline was used. In total, four systemic reactions occurred (two grade I and two grade II).
CONCLUSION
CONCLUSIONS
All doses of mannan-conjugated birch pollen allergoids can be considered as safe. Since the application of 10,000 mTU/mL resulted in the highest efficacy, this dose qualifies for further investigation.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Inmunotek
Informations de copyright
© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.
Références
D'Amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy. 2007;62:976-990. doi:10.1111/j.1398-9995.2007.01393.x
Mari A, Wallner M, Ferreira F. Fagales pollen sensitization in a birch-free area: a respiratory cohort survey using Fagales pollen extracts and birch recombinant allergens (rBet v 1, rBet v 2, rBet v 4). Clin Exp Allergy. 2003;33:1419-1428. doi:10.1046/j.1365-2222.2003.01773.x
Larsen JN, Broge L, Jacobi H. Allergy immunotherapy: the future of allergy treatment. Drug Discov Today. 2016;21:26-37. doi:10.1016/j.drudis.2015.07.010
Larche M, Akdis CA, Valenta R. Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol. 2006;6:761-771. doi:10.1038/nri1934
Visco V, Dolecek C, Denépoux S, et al. Human IgG monoclonal antibodies that modulate the binding of specific IgE to birch pollen Bet v 1. J Immunol. 1996;157:956-962.
Sondermann W, Reinboldt-Jockenhöfer F, Dissemond J, Pfaar O, Bingel U, Schedlowski M. Effects of patients' expectation in dermatology: evidence from experimental and clinical placebo studies and implications for dermatologic practice and research. Dermatology. 2021;237:857-871. doi:10.1159/000513445
Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol. 1985;76:397-401. doi:10.1016/0091-6749(85)90661-x
Bousquet J, Michel FB. Safety considerations in assessing the role of immunotherapy in allergic disorders. Drug Saf. 1994;10:5-17. doi:10.2165/00002018-199410010-00002
Heydenreich B, Bellinghausen I, Lorenz S, et al. Reduced in vitro T-cell responses induced by glutaraldehyde-modified allergen extracts are caused mainly by retarded internalization of dendritic cells. Immunology. 2012;136:208-217. doi:10.1111/j.1365-2567.2012.03571.x
Casanovas M, Gomez MJ, Carnes J, Fernandez-Caldas E. Skin tests with native, depigmented and glutaraldehyde polymerized allergen extracts. J Investig Allergol Clin Immunol. 2005;15:30-36.
Jensen-Jarolim E, Roth-Walter F, Jordakieva G, Pali-Scholl I. Allergens and adjuvants in allergen immunotherapy for immune activation, tolerance, and resilience. J Allergy Clin Immunol Pract. 2021;9:1780-1789. doi:10.1016/j.jaip.2020.12.008
Soria I, Alvarez J, Manzano AI, et al. Mite allergoids coupled to nonoxidized mannan from Saccharomyces cerevisiae efficiently target canine dendritic cells for novel allergy immunotherapy in veterinary medicine. Vet Immunol Immunopathol. 2017;190:65-72. doi:10.1016/j.vetimm.2017.07.004
Manzano AI, Javier Cañada F, Cases B, et al. Structural studies of novel glycoconjugates from polymerized allergens (allergoids) and mannans as allergy vaccines. Glycoconj J. 2016;33:93-101. doi:10.1007/s10719-015-9640-4
Liu J, Zhang X, Cheng Y, Cao X. Dendritic cell migration in inflammation and immunity. Cell Mol Immunol. 2021;18:2461-2471. doi:10.1038/s41423-021-00726-4
Schülke S, Gilles S, Jirmo AC, Mayer JU. Tissue-specific antigen-presenting cells contribute to distinct phenotypes of allergy. Eur J Immunol. 2023;e2249980:e2249980. doi:10.1002/eji.202249980
Eljaszewicz A, Ruchti F, Radzikowska U, et al. Trained immunity and tolerance in innate lymphoid cells, monocytes, and dendritic cells during allergen-specific immunotherapy. J Allergy Clin Immunol. 2021;147:1865-1877. doi:10.1016/j.jaci.2020.08.042
Sirvent S, Soria I, Cirauqui C, et al. Novel vaccines targeting dendritic cells by coupling allergoids to nonoxidized mannan enhance allergen uptake and induce functional regulatory T cells through programmed death ligand 1. J Allergy Clin Immunol. 2016;138:558-567.e511. doi:10.1016/j.jaci.2016.02.029
Soria I, López-Relaño J, Viñuela M, et al. Oral myeloid cells uptake allergoids coupled to mannan driving Th1/Treg responses upon sublingual delivery in mice. Allergy. 2018;73:875-884. doi:10.1111/all.13396
Benito-Villalvilla C, Pérez-Diego M, Angelina A, et al. Allergoid-mannan conjugates reprogram monocytes into tolerogenic dendritic cells via epigenetic and metabolic rewiring. J Allergy Clin Immunol. 2022;149:212-222.e219. doi:10.1016/j.jaci.2021.06.012
Benito-Villalvilla C, Soria I, Subiza JL, Palomares O. Novel vaccines targeting dendritic cells by coupling allergoids to mannan. Allergo J Int. 2018;27:256-262. doi:10.1007/s40629-018-0069-8
Pfaar O, Demoly P, Gerth van Wijk R, et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy. 2014;69:854-867. doi:10.1111/all.12383
Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy. 2007;62:1023-1028. doi:10.1111/j.1398-9995.2007.01469.x
Pfaar O, Bastl K, Berger U, et al. Defining pollen exposure times for clinical trials of allergen immunotherapy for pollen-induced rhinoconjunctivitis-an EAACI position paper. Allergy. 2017;72:713-722. doi:10.1111/all.13092
Shamji MH, Ljørring C, Francis JN, et al. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012;67:217-226. doi:10.1111/j.1398-9995.2011.02745.x
Juniper EF, Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy. 1991;21:77-83.
Ring J, Beyer K, Biedermann T, et al. Guideline for acute therapy and management of anaphylaxis: S2 guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German academy of Allergology and environmental medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (OGAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB). Allergo J Int. 2014;23:96-112. doi:10.1007/s40629-014-0009-1
Mosges R, Kasche EM, Raskopf E, et al. A randomized, double-blind, placebo-controlled, dose-finding trial with Lolium perenne peptide immunotherapy. Allergy. 2018;73:896-904. doi:10.1111/all.13358
Pfaar O, Lang S, Pieper-Fürst U, et al. Ultra-short-course booster is effective in recurrent grass pollen-induced allergic rhinoconjunctivitis. Allergy. 2018;73:187-195. doi:10.1111/all.13240
Mosges R, Bachert C, Panzner P, et al. Short course of grass allergen peptides immunotherapy over 3 weeks reduces seasonal symptoms in allergic rhinoconjunctivitis with/without asthma: a randomized, multicenter, double-blind, placebo-controlled trial. Allergy. 2018;73:1842-1850. doi:10.1111/all.13433
Pfaar O, Bachert C, Kuna P, et al. Sublingual allergen immunotherapy with a liquid birch pollen product in patients with seasonal allergic rhinoconjunctivitis with or without asthma. J Allergy Clin Immunol. 2019;143:970-977. doi:10.1016/j.jaci.2018.11.018
Novak N, Worm M, Staubach P, Jutel M, Sager A, Pfaar O. Subcutaneous birch pollen allergen immunotherapy with a depigmented polymerized extract shows only sustained and long-term efficacy in a subgroup of monosensitized adults and adolescents with allergic rhinitis. Clin Transl Allergy. 2022;12:e12185. doi:10.1002/clt2.12185
Biedermann T, Kuna P, Panzner P, et al. The SQ tree SLIT-tablet is highly effective and well tolerated: results from a randomized, double-blind, placebo-controlled phase III trial. J Allergy Clin Immunol. 2019;143:1058-1066.e1056. doi:10.1016/j.jaci.2018.12.1001
Mengi E, Kara CO, Alptürk U, Topuz B. The effect of face mask usage on the allergic rhinitis symptoms in patients with pollen allergy during the covid-19 pandemic. Am J Otolaryngol. 2022;43:103206. doi:10.1016/j.amjoto.2021.103206
Bahbah F, Gentil C, Sousa-Pinto B, et al. Patient-reported outcome measures in birch pollen allergic patients treated with sublingual immunotherapy reflect real life. Allergy. 2022;78:1113-1116. doi:10.1111/all.15550
Primov-Fever A, Amir O, Roziner I, Maoz-Segal R, Alon EE, Yakirevitch A. How face masks influence the sinonasal quality of life during the COVID-19 pandemic. Eur Arch Otorhinolaryngol. 2021;278:4805-4811. doi:10.1007/s00405-021-06752-2
Schmidt-Weber CB, Blaser K. New insights into the mechanisms of allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol. 2005;5:525-530.
Walker SM, Durham SR, Till SJ, et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy. 2011;41:1177-1200. doi:10.1111/j.1365-2222.2011.03794.x
Nieto A, Mazón Á, Nieto M, et al. First-in-human phase 2 trial with mite allergoids coupled to mannan in subcutaneous and sublingual immunotherapy. Allergy. 2022;77:3096-3107. doi:10.1111/all.15374
Subbarayal B, Schiller D, Möbs C, et al. Kinetics, cross-reactivity, and specificity of Bet v 1-specific IgG4 antibodies induced by immunotherapy with birch pollen. Allergy. 2013;68:1377-1386. doi:10.1111/all.12236
Calderon MA, Alves B, Jacobson M, et al. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev. 2007;2007:CD001936. doi:10.1002/14651858.CD001936.pub2
Pfaar O, Klimek L, Jutel M, et al. COVID-19 pandemic: practical considerations on the organization of an allergy clinic-an EAACI/ARIA Position Paper. Allergy. 2021;76:648-676. doi:10.1111/all.14453